Insider Trading activities of Anadys Pharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anadys Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Anadys Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Anadys Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is ANDS. The reporting company's CIK number is 1128495.
The total value of stock buying since 2005 is $9,713,261.
The total value of stock sales since 2005 is $35,231,389.
The total value of stock option exercises since 2005 is $611,362.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Anadys Pharmaceuticals Inc (ANDS).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2011-10 0 $0 6,267,718 $23,065,202 0 $0
2011-01 34,209 $48,234 0 $0 0 $0
2010-12 2,862,004 $3,793,096 0 $0 0 $0
2010-10 2,451,389 $4,141,450 0 $0 0 $0
2010-09 58,000 $102,740 0 $0 0 $0
2010-08 268,900 $493,678 0 $0 0 $0
2010-07 86,800 $169,592 0 $0 0 $0
2008-10 0 $0 1,380,000 $3,008,400 0 $0
2008-08 10,000 $27,000 0 $0 0 $0
2008-05 0 $0 0 $0 33,898 $99,999
2007-11 6,800 $14,189 0 $0 0 $0
2007-09 107,638 $248,280 0 $0 0 $0
2007-08 298,354 $643,496 0 $0 0 $0
2007-02 4,170 $14,386 0 $0 0 $0
2007-01 0 $0 0 $0 25,000 $73,750
2006-12 2,200 $10,120 0 $0 0 $0
2006-11 0 $0 100 $500 0 $0
2006-10 0 $0 200 $2,042 0 $0
2006-05 0 $0 6,500 $71,182 23,301 $154,413
2006-04 0 $0 11,500 $170,204 1,500 $4,425
2006-03 0 $0 103,115 $1,519,512 90,000 $265,500
2006-02 0 $0 15,870 $193,871 1,500 $4,425
2006-01 0 $0 10,181 $107,492 3,000 $8,850
2005-12 0 $0 5,000 $40,740 0 $0
2005-11 0 $0 5,000 $52,920 0 $0
2005-10 0 $0 5,000 $54,490 0 $0
2005-09 0 $0 5,000 $66,895 0 $0
2005-08 0 $0 5,000 $64,185 0 $0
2005-07 0 $0 5,000 $56,220 0 $0
2005-06 0 $0 837,768 $6,757,534 0 $0
2004-03 1,000 $7,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Anadys Pharmaceuticals Inc insiders (ANDS)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2011-10-21 Qvt Fund Lp (10% Owner) Sale 364,918 3.68 1,342,898
2011-10-20 Qvt Fund Lp (10% Owner) Sale 5,252,700 3.68 19,329,936
2011-10-17 Qvt Fund Lp (10% Owner) Sale 650,100 3.68 2,392,368
2011-01-03 Qvt Fund Lp (10% Owner) Buy 34,209 1.41 48,234
2010-12-30 Qvt Fund Lp (10% Owner) Buy 300 1.48 444
2010-12-29 Qvt Fund Lp (10% Owner) Buy 317,014 1.46 461,255
2010-12-28 Qvt Fund Lp (10% Owner) Buy 544,690 1.39 757,119
2010-12-27 Qvt Fund Lp (10% Owner) Buy 1,714,210 1.30 2,228,473
2010-12-23 Qvt Fund Lp (10% Owner) Buy 285,790 1.21 345,805
2010-10-20 Qvt Fund Lp (10% Owner) Buy 150,000 1.65 247,500
2010-10-15 Qvt Fund Lp (10% Owner) Buy 2,301,389 1.69 3,893,950
2010-09-16 Qvt Fund Lp (10% Owner) Buy 8,000 1.78 14,240
2010-09-10 Qvt Fund Lp (10% Owner) Buy 25,000 1.80 45,000
2010-09-01 Qvt Fund Lp (10% Owner) Buy 25,000 1.74 43,500
2010-08-30 Qvt Fund Lp (10% Owner) Buy 25,000 1.77 44,250
2010-08-27 Qvt Fund Lp (10% Owner) Buy 6,000 1.75 10,500
2010-08-26 Qvt Fund Lp (10% Owner) Buy 15,700 1.75 27,475
2010-08-25 Qvt Fund Lp (10% Owner) Buy 17,400 1.70 29,580
2010-08-24 Qvt Fund Lp (10% Owner) Buy 34,900 1.73 60,377
2010-08-23 Qvt Fund Lp (10% Owner) Buy 27,000 1.79 48,330
2010-08-20 Qvt Fund Lp (10% Owner) Buy 4,000 1.77 7,080
2010-08-19 Qvt Fund Lp (10% Owner) Buy 16,000 1.79 28,640
2010-08-17 Qvt Fund Lp (10% Owner) Buy 5,000 1.80 9,000
2010-08-16 Qvt Fund Lp (10% Owner) Buy 35,000 1.86 65,100
2010-08-12 Qvt Fund Lp (10% Owner) Buy 32,500 1.94 63,050
2010-08-03 Qvt Fund Lp (10% Owner) Buy 50,400 1.99 100,296
2010-07-06 Qvt Fund Lp (10% Owner) Buy 30,000 1.98 59,400
2010-07-02 Qvt Fund Lp (10% Owner) Buy 56,800 1.94 110,192
2008-10-18 Deerfield Special Situations Fund International Lt (10% Owner) Sale 920,000 2.18 2,005,600
2008-08-26 Scangos George A (Director) Buy 10,000 2.70 27,000
2008-05-30 Worland Stephen T (President and CEO) Option Ex 33,898 2.95 99,999
2007-11-16 Glover James T (SVP, Operations and CFO) Buy 600 2.00 1,200
2007-11-15 Glover James T (SVP, Operations and CFO) Buy 1,200 2.08 2,490
2007-11-09 Glover James T (SVP, Operations and CFO) Buy 3,401 2.10 7,142
2007-11-08 Glover James T (SVP, Operations and CFO) Buy 1,599 2.10 3,357
2007-09-14 Papadopoulos Stelios (Director) Buy 2,869 2.30 6,598
2007-09-06 Papadopoulos Stelios (Director) Buy 200 2.30 459
2007-09-05 Papadopoulos Stelios (Director) Buy 89,333 2.30 205,465
2007-09-04 Worland Stephen T (President and CEO) Buy 13,236 2.34 31,038
2007-09-04 Williams Douglas E (Director) Buy 2,000 2.36 4,720
2007-08-31 Worland Stephen T (President and CEO) Buy 12,200 2.12 25,815
2007-08-31 Scangos George A (Director) Buy 22,188 2.18 48,480
2007-08-31 Papadopoulos Stelios (Director) Buy 32,913 2.22 73,099
2007-08-30 Worland Stephen T (President and CEO) Buy 124,564 2.00 249,128
2007-08-17 Papadopoulos Stelios (Director) Buy 38,989 2.15 83,826
2007-08-16 Xanthopoulos Kleanthis G (Director) Buy 6,500 2.15 13,955
2007-08-15 Glover James T (SVP, Operations and CFO) Buy 1,000 2.17 2,169
2007-08-14 Fritz Lawrence C (President and CEO) Buy 5,691 2.20 12,497
2007-08-13 Fritz Lawrence C (President and CEO) Buy 14,309 2.29 32,767
2007-08-10 Fritz Lawrence C (President and CEO) Buy 40,000 2.54 101,760
2007-02-28 Glover James T (SVP, Operations and CFO) Buy 4,170 3.45 14,386
2007-01-12 Worland Stephen T (President, Pharmaceuticals) Option Ex 25,000 2.95 73,750
2006-12-11 Glover James T (SVP, Operations and CFO) Buy 2,200 4.60 10,120
2006-11-14 Xanthopoulos Kleanthis G (CEO and President) Sale 100 5.00 500
2006-10-09 Yaroshevsky Glanville Mary (Vice President, Huma) Sale 200 10.21 2,042
2006-05-18 Averett Devron R (Chief Scientific Officer) Option Ex 14,534 6.88 99,992
2006-05-15 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 10.49 52,440
2006-05-08 Yaroshevsky Glanville Mary (Vice President, Human Capital) Sale 1,500 12.50 18,742
2006-05-08 Yaroshevsky Glanville Mary (Vice President, Human Capital) Option Ex 1,500 2.95 4,425
2006-04-17 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 14.82 74,125
2006-04-10 Reed Elizabeth E (Senior Director, Legal Affairs) Sale 1,500 13.71 20,559
2006-04-10 Reed Elizabeth E (Senior Director, Legal Affairs) Option Ex 1,500 2.95 4,425
2006-04-03 Averett Devron R (Chief Scientific Officer) Sale 5,000 15.10 75,520
2006-03-20 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 15.36 76,800
2006-03-16 Worland Stephen T (EVP, Pharmaceuticals) Sale 4,000 16.00 64,000
2006-03-07 Yaroshevsky Glanville Mary (Vice President, Human Capital) Sale 1,115 14.72 16,412
2006-03-07 Xanthopoulos Kleanthis G (CEO and President) Sale 60,000 14.67 880,200
2006-03-07 Xanthopoulos Kleanthis G (CEO and President) Option Ex 60,000 2.95 177,000
2006-03-02 Worland Stephen T (EVP, Pharmaceuticals) Sale 3,000 14.00 42,000
2006-02-28 Xanthopoulos Kleanthis G (CEO and President) Sale 6,141 12.99 79,747
2006-02-21 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 11.81 59,050
2006-02-17 Averett Devron R (Chief Scientific Officer) Sale 3,229 12.02 38,822
2006-02-13 Reed Elizabeth E (Senior Director, Legal Affairs) Sale 1,500 10.84 16,252
2006-02-13 Reed Elizabeth E (Senior Director, Legal Affairs) Option Ex 1,500 2.95 4,425
2006-01-17 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 11.03 55,134
2006-01-09 Yaroshevsky Glanville Mary (Vice President, Huma) Sale 3,681 10.14 37,343
2006-01-09 Yaroshevsky Glanville Mary (Vice President, Huma) Option Ex 1,500 2.95 4,425
2006-01-09 Reed Elizabeth E (Senior Director, Leg) Sale 1,500 10.01 15,015
2006-01-09 Reed Elizabeth E (Senior Director, Leg) Option Ex 1,500 2.95 4,425
2005-12-19 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 8.15 40,740
2005-11-21 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 10.58 52,920
2005-10-17 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 10.90 54,490
2005-09-19 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 13.38 66,895
2005-08-15 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 12.84 64,185
2005-07-18 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 11.24 56,220
2005-06-21 Xanthopoulos Kleanthis G (CEO and President) Sale 5,000 8.62 43,105
2005-06-06 Hbm Bioventures Ag (10% Owner) Sale 288,604 7.62 2,199,739
2005-06-03 Hbm Bioventures Ag (10% Owner) Sale 100,000 8.01 801,099
2005-06-02 Hbm Bioventures Ag (10% Owner) Sale 247,256 8.37 2,073,518
2004-03-31 Scangos George A (Director) Buy 1,000 7.00 7,000

Insider trading activities including stock purchases, stock sales, and option exercises of ANDS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Anadys Pharmaceuticals Inc (symbol ANDS, CIK number 1128495) see the Securities and Exchange Commission (SEC) website.